Sangamo Therapeutics Stock Today
| SGMO Stock | USD 0.84 0.00 0.000004% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Sangamo Therapeutics is selling at 0.83999997 as of the 21st of March 2025; that is 0 percent decrease since the beginning of the trading day. The stock's open price was 0.8391. Sangamo Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of April 2000 | Category Healthcare | Classification Health Care |
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo Therapeutics, Inc. The company has 208.65 M outstanding shares of which 25.46 M shares are at this time shorted by private and institutional investors with about 7.0 trading days to cover. More on Sangamo Therapeutics
Moving against Sangamo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Sangamo Stock Highlights
| President | Jason Fontenot | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSangamo Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sangamo Therapeutics' financial leverage. It provides some insight into what part of Sangamo Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sangamo Therapeutics (SGMO) is traded on NASDAQ Exchange in USA. It is located in 501 Canal Blvd, Richmond, CA, United States, 94804 and employs 16 people. Sangamo Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 181.4 M. Sangamo Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 208.65 M outstanding shares of which 25.46 M shares are at this time shorted by private and institutional investors with about 7.0 trading days to cover.
Sangamo Therapeutics currently holds about 315.72 M in cash with (67.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sangamo Therapeutics Probability Of Bankruptcy
Ownership AllocationSangamo Therapeutics shows a total of 208.65 Million outstanding shares. About 70.36 % of Sangamo Therapeutics outstanding shares are held by general public with 2.16 (%) owned by insiders and only 27.48 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sangamo Ownership Details
Sangamo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-12-31 | 1.6 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.1 M | |
| Two Sigma Investments Llc | 2024-12-31 | 1 M | |
| Citadel Advisors Llc | 2024-12-31 | 804.3 K | |
| Hightower Advisors, Llc | 2024-12-31 | 756.8 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 742.5 K | |
| Longwood Capital Partners Llc | 2024-12-31 | 740 K | |
| Squarepoint Ops Llc | 2024-12-31 | 710.4 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 707.6 K | |
| Vanguard Group Inc | 2024-12-31 | 9.4 M | |
| Wasatch Advisors Lp | 2024-12-31 | 9.2 M |
Sangamo Therapeutics Historical Income Statement
Sangamo Stock Against Markets
Sangamo Therapeutics Corporate Management
| Phillip Ramsey | Head Operations | Profile | |
| David Ojala | Scientist Research | Profile | |
| Mark McClung | Ex COO | Profile | |
| Stephanie CLP | Head Management | Profile | |
| Whitney Jones | VP Officer | Profile | |
| Andrew Ramelmeier | Ex Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth 2.698 | Return On Assets | Return On Equity |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.